RGNX BTFD

RGNX sold off 12% today on news of a partial clinical hold on an NVS gene therapy trial using its vector.
After reading the press release I think this was an overreaction and the stock price will bounce back swiftly into RGNX earnings catalyst on 11/08/2019. It is sold off right to the bottom of its channel making for a beautiful setup!